Breaking News, Financial News

Catalent 2Q Results

Biologics revenue was $446 million in the quarter, down 23%, primarily impacted by a decline in demand for COVID-19 related programs.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent 2Q Revenues: $1.03 billion (-10%)   2Q Loss: $204 million (earnings were $81 million 2Q22) YTD Revenues: $2.0 billion (-7%) YTD Loss: $963 million (earnings were $81 million YTD22) Comments: Results in the quarter were primarily impacted by a decline in demand for COVID-19 related programs. Biologics revenue was $446 million in the quarter, down 23%. Pharma and Consumer health revenue was $587 million, up 3%.     For the three months ended June 30, 2023, fixed asset impairment ch...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters